Bacteroides xylanisolvens
Selected indexed studies
- Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. (Nature, 2022) [PMID:36261549]
- Bacteroides xylanisolvens possesses a potent anti-hyperuricemia effect in goslings fed on a high-protein diet. (Front Microbiol, 2023) [PMID:37455728]
- Degradation of xylan by human gut Bacteroides xylanisolvens XB1A. (Carbohydr Polym, 2023) [PMID:37230606]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Insight into immunoregulatory and neuromodulatory capability of Bacteroides cellulosilyticus and Bacteroides xylanisolvens human gut microbiota isolates. (2025) pubmed
- Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. (2022) pubmed
- Bacteroides xylanisolvens possesses a potent anti-hyperuricemia effect in goslings fed on a high-protein diet. (2023) pubmed
- Degradation of xylan by human gut Bacteroides xylanisolvens XB1A. (2023) pubmed
- Human symbiont Bacteroides xylanisolvens attenuates NASH through intestinal nicotine catabolism. (2023) pubmed
- Fucoidan-driven Bacteroides xylanisolvens HS-1 alleviates hyperuricemia by promoting intestinal uric acid excretion via the PPARγ/ABCG2 signaling pathway. (2025) pubmed
- The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults. (2022) pubmed
- A novel Bacteroides metallo-β-lactamase (MBL) and its gene (crxA) in Bacteroides xylanisolvens revealed by genomic sequencing and functional analysis. (2022) pubmed
- Bacteroides xylanisolvens sp. nov., a xylan-degrading bacterium isolated from human faeces. (2008) pubmed
- Cross-feeding-based rational design of a probiotic combination of Bacterides xylanisolvens and Clostridium butyricum therapy for metabolic diseases. (2025) pubmed